Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (St ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary. Raul Rodriguez - President and CEO Dave Santos - EVP and Chief Commercial Officer Wolfgang Dummer - EVP and Chief Medical Officer Dean Schorno - EVP and Chief Financial Officer Conference Call Participants Carly Kenselaar - Citi Eun Yang - Jefferies Do Kim - Piper Sandler Kristen Kluska - Cantor Fitzgerald Gary Nachman - BMO Capita ...

| --- | --- | --- | |--------------------------------|-------|-------| | | | | | | | | | Q4 & YE 2022 Financial Results | | | | Presentation March 7, 2023 | | | | | | | Forward-Looking Statements Any statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the PSLRA. Forward-looking statements can be identified by words such as "pla ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-29889 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or or ...

! The first patients have been dosed in an open-label, Phase 1b clinical trial of study in lowrisk MDS4. The primary endpoint for this trial is safety with key secondary endpoints including preliminary efficacy Dual Inhibition of IRAK1 and IRAK4 Provides Stronger Suppression of Inflammatory Cytokines Compared to IRAK4-selective Inhibitor2 Proof-of-Mechanism First-In-Human study enrolled 82 adults to characterize the safety, PK, PD of R835 IL6 25 1R835 is an investigational compound not approved by the FDA. ...

Financial Data and Key Metrics Changes - The company reported total revenue of $22.4 million for Q3 2022, which includes net product sales from TAVALISSE of $19.2 million, reflecting a 20% increase compared to the same quarter last year [55][53] - The gross to net adjustment for TAVALISSE was approximately 28.9% for Q3 2022, with expectations for a 30% adjustment in Q4 2022 [53][54] - The company ended the quarter with cash, cash equivalents, and short-term investments of $81.6 million [57] Business Line Data and Key Metrics Changes - TAVALISSE achieved the highest quarterly net product sales since its launch, with 2,026 bottles shipped, representing nearly 19% growth year-over-year [40][41] - The company is excited about the potential of olutasidenib, which is nearing approval with a PDUFA date set for February 15, 2023 [9][60] - The Phase 2 registrational study of olutasidenib showed a 35% composite endpoint achievement, with over 90% of responders achieving complete remission [22][28] Market Data and Key Metrics Changes - The company noted that the market for AML treatments is significant, with over 20,000 new diagnoses expected in 2022 [14] - The company is focusing on the IDH1 mutation, which is present in 6% to 9% of AML patients, indicating a well-defined patient population for olutasidenib [16][32] Company Strategy and Development Direction - The company aims to expand its hematology-oncology portfolio with olutasidenib and is preparing for its launch [9][38] - The company is also exploring partnerships to create value, including collaborations for fostamatinib in COVID-19 and the RIP1 inhibitor program with Eli Lilly [12][50] - The company is committed to increasing awareness of TAVALISSE among prescribing clinicians to drive new patient starts [41][42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming launch of olutasidenib and its potential to positively impact the lives of patients with relapsed refractory IDH1 positive AML [35][60] - The company anticipates a significant decrease in operating expenses in 2023 due to completed Phase 3 studies and workforce reductions [57][92] - Management highlighted the importance of the upcoming ASH conference for increasing awareness of Rigel's hem-onc pipeline [42] Other Important Information - The company is exploring options for fostamatinib in COVID-19 but does not plan to commercialize it independently [12] - The company is preparing for a Phase 2 study of the RIP1 inhibitor R552 in collaboration with Eli Lilly, expected to start in the first half of 2023 [50] Q&A Session Summary Question: What drives the better durability seen with olutasidenib compared to TIBSOVO? - Management acknowledged the significant increase in duration of CR + CRh response and noted that better initial responses may contribute to longer-term outcomes [65][66][70] Question: What were the headwinds for TAVALISSE in Q3? - Management indicated that while there was flat growth compared to Q2, year-over-year growth was strong, driven by new patient starts [72][74] Question: What is the expected milestone payment from Kissei for TAVALISSE in Japan? - Management expects a $20 million milestone payment upon approval, likely in Q1 of next year [86][88] Question: What is the current size of the sales force and any potential changes? - The sales force remains at 54 territories, with no changes anticipated due to the focus on higher-tier targets [99][101] Question: Are there any concerns regarding QTC prolongation with olutasidenib? - Management confirmed no evidence of QTC prolongation with olutasidenib and noted that differentiation syndrome was managed effectively [105][106]

| --- | --- | --- | |------------------------------|-------|-------| | | | | | | | | | Q3 2022 Financial Results | | | | Presentation November 3,2022 | | | | | | | 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, the development and commercialization of olutasidenib; the timing of launch of olutasidenib; the progress of the RIPK1 inhibitor program in collabo ...

Table of Contents FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 (Mark One) Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 ...

| --- | --- | --- | |----------------------------|-------|-------| | | | | | | | | | | | | | Q2 2022 Financial Results | | | | Presentation August 2,2022 | | | | | | | 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, Rigel's licensing agreement with Forma Therapeutics Holdings, Inc. ("Forma Therapeutics") and the success thereof; Rigel's ability to successfu ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Dolly Vance - Executive Vice President, Corporate Affairs and General Counsel Raul Rodriguez - President and Chief Executive Officer Dave Santos - Executive Vice President and Chief Commercial Officer Wolfgang Dummer - Executive Vice President and Chief Medical Officer Dean Schorno - Executive Vice President and Chief Financial Officer Jorge Cortes - Director, Georgia Cancer Center. Augu ...